Susquehanna International Group, LLP Beyond Spring Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Beyond Spring Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 20,700 shares of BYSI stock, worth $36,225. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,700

Previous 35,700 42.02%

Holding current value

$36,225

Previous $85,000 44.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $75,309 - $140,526	-77,639 Reduced 74.96%	25,939 $26,000
Q2 2022 Aug 15, 2022	BUY	$1.13 - $2.66 $85,371 - $200,963	75,550 Added 269.55%	103,578 $149,000
Q1 2022 May 16, 2022	SELL	$1.68 - $5.01 $121,511 - $362,363	-72,328 Reduced 72.07%	28,028 $62,000
Q4 2021 Feb 14, 2022	SELL	$4.02 - $16.84 $597,275 - $2.5 Million	-148,576 Reduced 59.69%	100,356 $455,000
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $1.63 Million - $5.5 Million	175,617 Added 239.54%	248,932 $3.92 Million
Q2 2021 Aug 11, 2021	SELL	$9.37 - $12.12 $61,364 - $79,373	-6,549 Reduced 8.2%	73,315 $765,000
Q1 2021 May 17, 2021	BUY	$10.61 - $15.77 $689,692 - $1.03 Million	65,004 Added 437.44%	79,864 $884,000
Q4 2020 Feb 16, 2021	BUY	$10.21 - $17.31 $151,720 - $257,226	14,860 New	14,860 $181,000
Q4 2019 Feb 14, 2020	SELL	$11.83 - $18.68 $129,562 - $204,583	-10,952 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$15.33 - $23.85 $167,894 - $261,205	10,952 New	10,952 $198,000
Q2 2018 Aug 14, 2018	SELL	$26.29 - $33.0 $251,726 - $315,975	-9,575 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$20.39 - $33.94 $195,234 - $324,975	9,575 New	9,575 $245,000

Others Institutions Holding BYSI

# of Institutions

Shares Held

5.55M

Call Options Held

26K

Put Options Held

2.4K

View Full List

About BeyondSpring Inc.

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $68.1M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

More about BYSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Beyond Spring Inc. Transaction History